Moderna (NASDAQ:MRNA) shares fell ~5% in the premarket on Friday after the COVID-19 vaccine maker, with its Q4 2024 results, topped the consensus for revenue but missed Street forecasts for earnings following a ~66% YoY contraction in its topline.

The Cambridge, Massachusetts-based